Denali Therapeutics (DNLI) Short term Debt (2022)
Denali Therapeutics (DNLI) posted quarterly Short term Debt of $4.4 million for Q4 2022, up 204.09% quarter-over-quarter from $1.4 million in Q3 2022.
Denali Therapeutics (DNLI) Short term Debt (2022) Analysis & Trends
Denali Therapeutics (DNLI) has reported Short term Debt for 1 consecutive years, with $4.4 million the latest figure, recorded in Q4 2022.
- In Q4 2022, Short term Debt changed N/A year-over-year to $4.4 million; the TTM figure through Dec 2022 stood at $4.4 million (changed N/A YoY), while the FY2022 annual figure was $4.4 million, changed N/A from the prior year.
- Short term Debt grew to $4.4 million in Q4 2022 per DNLI's latest filing, from $1.4 million in the prior quarter.
- Across five years, Short term Debt topped out at $4.4 million in Q4 2022 and bottomed at $1.4 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 4.39 Mn |
| Sep 30, 2022 | 1.44 Mn |
| Mar 31, 2022 | 2.71 Mn |